L Parker Gregg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5014333/publications.pdf

Version: 2024-02-01

933447 752698 22 449 10 20 citations g-index h-index papers 22 22 22 565 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	7.4	99
2	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. American Journal of Kidney Diseases, 2018, 72, 728-744.	1.9	58
3	Fatigue in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1445-1455.	4.5	53
4	Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 457-464.	2.0	46
5	Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease. American Journal of Nephrology, 2018, 47, 395-405.	3.1	35
6	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	3.1	31
7	Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes. Journal of the American Heart Association, 2017, 6, .	3.7	24
8	Effects of the 2021 CKD-EPI Creatinine eGFR Equation among a National US Veteran Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 283-285.	4.5	22
9	A Systematic Review and Meta-Analysis of Depression and Protein–Energy Wasting in Kidney Disease. Kidney International Reports, 2020, 5, 318-330.	0.8	20
10	Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1–5. Hypertension, 2021, 77, 948-959.	2.7	14
11	Using dipstick urinalysis to predict development of acute kidney injury in patients with COVID-19. BMC Nephrology, 2022, 23, 50.	1.8	9
12	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. American Journal of Kidney Diseases, 2020, 75, 457-460.	1.9	6
13	Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. American Heart Journal, 2021, , .	2.7	5
14	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. Kidney360, 2020, 1, 436-446.	2.1	4
15	Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. American Journal of Kidney Diseases, 2021, 78, 700-708.e1.	1.9	4
16	Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19. Kidney Medicine, 2022, 4, 100463.	2.0	4
17	Diagnosis and Management of Depression in Patients With Kidney Disease. Seminars in Nephrology, 2021, 41, 505-515.	1.6	4
18	Screening for Depression in People with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1702-1704.	4.5	3

#	Article	IF	CITATIONS
19	The effects of extracellular volume and intradialytic peripheral resistance changes on ambulatory blood pressure in hemodialysis patients with and without recurrent intradialytic hypertension. CKJ: Clinical Kidney Journal, 2021, 14, 1450-1457.	2.9	3
20	Are All SGLT2 Inhibitors Created Equal?. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1309-1311.	4.5	3
21	Early eGFR decline after SGLT2i initiation: knowns and unknowns. Kidney International, 2021, 99, 548-550.	5.2	2
22	Considerations in the Study of Body Mass Index Variability. Journal of the American Society of Nephrology: JASN, 2021, 32, 2395-2397.	6.1	0